Analytical Data
-
基因名
Ighg1
- Application
-
别名
Ighg1；Immunoglobulin heavy constant gamma 1
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P01857
-
表达区间
1-330aa
-
氨基酸序列
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK
-
分子量
36 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Ighg1 recombinant protein research primarily focuses on the immunoglobulin G (IgG) subclass known as IgG1, which plays a crucial role in the immune response. IgG1 is the most abundant antibody in human serum, responsible for neutralizing pathogens, facilitating phagocytosis, and activating complement pathways. The production and characterization of Ighg1 recombinant protein have significant implications for therapeutic applications, including vaccine development, antibody engineering, and disease treatment. Advances in recombinant DNA technology have enabled the expression of Ighg1 in various systems, leading to insights into its structural and functional properties. Moreover, understanding the variability of IgG1 in response to different immunogens can improve vaccine efficacy and inform the design of monoclonal antibodies for specific targets in diseases such as cancer and autoimmune disorders. Additionally, the assessment of Ighg1 glycosylation patterns is vital, as these modifications can influence its stability, serum half-life, and overall therapeutic effectiveness. Research in this area continues to explore new methods for optimizing the yield and functionality of Ighg1 recombinant proteins, paving the way for innovative treatments and enhancing our understanding of the immune system's complexities.
